Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.75 |
| ▸ | NPC1 | O15118 | 13/20 | 0.71 |
| ▸ | RAB9A | P51151 | 12/20 | 0.71 |
| ▸ | HPGD | P15428 | 7/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.71 |
| ▸ | RELA | Q04206 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494939 | 0.86 | ALDH1A1 (0.77) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL4728069 | 0.86 | NPC1 (0.67) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL19322176 | 0.84 | KDM4E (0.82) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL1662102 | 0.83 | KDM4E (0.63) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL1494680 | 0.83 | NPC1 (0.72) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL2427998 | 0.82 | RAB9A (0.64) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL12799208 | 0.81 | RAB9A (0.65) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL1494571 | 0.81 | KDM4E (0.77) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL4727621 | 0.81 | SMN1; SMN2 (0.71) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL30366944 | 0.81 | RAB9A (0.69) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | claimed |
| US-10370373-B2 | Antitumor derivatives for differentiation therapy | THE CLEVELAND CLINIC FOUNDATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194764-A1 | ANTITUMOR DERIVATIVES FOR DIFFERENTIATION THERAPY | CLEVELAND CLINIC FOUND (US) | 2018-07-12 | — | — | US | disclosed |
| US-9926316-B2 | Antitumor derivatives for differentiation therapy | THE CLEVELAND CLINIC FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170253589-A1 | ANTITUMOR DERIVATIVES FOR DIFFERENTIATION THERAPY | THE CLEVELAND CLINIC FOUNDATION | 2017-09-07 | — | — | US | disclosed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009077956-A2 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194764-A1 | ANTITUMOR DERIVATIVES FOR DIFFERENTIATION THERAPY | MYD88, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | KDM4E 1060/4885SMN1; SMN2 841/4885ALDH1A1 3309/4885 |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | SHH, SMO, GLI1 | KDM4E 2294/4885SMN1; SMN2 4057/4885ALDH1A1 410/4885 |
| US-20170253589-A1 | ANTITUMOR DERIVATIVES FOR DIFFERENTIATION THERAPY | MYD88, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | KDM4E 1060/4885SMN1; SMN2 841/4885ALDH1A1 3309/4885 |
| US-10370373-B2 | Antitumor derivatives for differentiation therapy | MYD88, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | KDM4E 1060/4885SMN1; SMN2 841/4885ALDH1A1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.